917506-27-5

Basic information

• Product Name: (2S,4aS,6aR,7R,9S,10aS,10bR)-9-(4-nitrobenzoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1c]pyran-7-carboxylic acid methyl ester
• Synonyms: (2S,4aS,6aR,7R,9S,10aS,10bR)-9-(4-nitrobenzoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1c]pyran-7-carboxylic acid methyl ester
• CAS NO: 917506-27-5
• Molecular Weight: 539.539
• Mol File: 917506-27-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2S,4aS,6aR,7R,9S,10aS,10bR)-9-(4-nitrobenzoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1c]pyran-7-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4aS,6aR,7R,9S,10aS,10bR)-9-(4-nitrobenzoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1c]pyran-7-carboxylic acid methyl ester(917506-27-5)
• EPA Substance Registry System: (2S,4aS,6aR,7R,9S,10aS,10bR)-9-(4-nitrobenzoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1c]pyran-7-carboxylic acid methyl ester(917506-27-5)

Safety Data

• Hazardous Substances Data: 917506-27-5(Hazardous Substances Data)

Upstream product

• 92545-30-7 salvinorin B 
• 122-04-3 4-nitro-benzoyl chloride 
• 62-23-7 4-nitro-benzoic acid 

Relevant articles and documents

Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability

Opioids are widely used to treat millions suffering from pain, but their analgesic utility is limited due to associated side effects. Herein we report the development and evaluation of a chemical probe exhibiting analgesia and reduced opioid-induced side effects. This compound, kurkinorin (5), is a potent and selective μ-opioid receptor (MOR) agonist (EC50 = 1.2 nM, >8000 μ/κ selectivity). 5 is a biased activator of MOR-induced G-protein signaling over β-arrestin-2 recruitment. Metadynamics simulations of 5's binding to a MOR crystal structure suggest energetically preferred binding modes that differ from crystallographic ligands. In vivo studies with 5 demonstrate centrally mediated antinociception, significantly reduced rewarding effects, tolerance, and sedation. We propose that this novel MOR agonist may represent a valuable tool in distinguishing the pathways involved in MOR-induced analgesia from its side effects.

OPIOID RECEPTOR LIGANDS

The invention provides novel compounds of formula (I), (II), (III), and (IV). The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administer